Behavioural problems associated with dementia: The role of newer antipsychotics

Drugs and Aging

Volumn 14, Issue 1, 1999, Pages 41-54

  Stoppe, Gabriela ^a   Brandt, Claudia A ^a   Staedt, Jürgen H ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TRAZODONE; ZIPRASIDONE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANTISOCIAL BEHAVIOR; ANXIETY NEUROSIS; ARTICLE; BEHAVIOR DISORDER; DELUSION; DEMENTIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HOSTILITY; HUMAN; INCONTINENCE; LEWY BODY; NURSING HOME; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEDATION; SELF CARE; SLEEP DISORDER; STEREOTYPY; SYMPTOM; VISUAL IMPAIRMENT; VOCALIZATION; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; DEMENTIA; HUMANS;

EID: 0033007282     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914010-00003     Document Type: Article

References (165)

1. 1. Ott A, Breteler M, van Harskanip F, et al. Prevalence of Alzheimers disease and vascular dementia: association with education: the Rotterdam Study. BMJ 1995; 310: 970-3
2. 2. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551-6
3. 3. Morgan K, Lilley JM, Arie T, et al. Incidence of dementia in a representative British sample. Br J Psychiatry 1993; 163: 467-70
4. 4. Rovner BW, German PS, Broadhead J, et al. The prevalence and management of dementia and other psychiatric disorders in nursing homes. Int Psychogeriatr 1990; 2: 13-24
5. 5. Tariot PN, Podgorski CA, Blazina L, et al. Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993; 150: 1063-9
6. 6. Skoog I, Nilsson L, Palmertz B, et al. A population based study of dementia in 85 year-olds. N Engl J Med 1993; 328: 153-8
7. 7. Rapp MS, Flint AJ, Herrman N, et al. Behavioural disturbances in the demented elderly: phenomenology, pharmacotherapy and behavioural management. Can J Psychiatry 1992; 37: 651-7
8. 8. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimers disease: phenomenology and treatment. J Clin Psychiatry 1987; 5 Suppl. 9-15
9. 9. Beck C, Frank L, Chumbler NR, et al. Correlates of disruptive behavior in severely cognitively impaired nursing home residents. Gerontologist 1998; 38: 189-98
10. 10. Pruchno RA, Michaels JE, Potashnik S. Predictors for institutionalization among Alzheimer disease victims with caregiving spouses. J Gerontol 1990; 45 Suppl. 6: 259-66
11. 11. O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992; 5: 45-52
12. 12. Class CA, Schneider L, Farlow MR. Optimal management of behavioural disorders associated with dementia. Drugs Aging 1997; 10: 95-106
13. 13. Cohen-Mansfield J, Werner P. Longitudinal changes in behavioral problems in old age: a study in an adult day care population. J Gerontol A Biol Sci Med Sci 1998; 53: M65-71
14. 14. Haupt M, Janner M, Stierstorfer A, et al. Das Erscheinungsbild und die Verlaufsstabilitat von nicht-kognitiven Symptommustern bei Patienten mit Alzheimerscher Krankheit. Fortschr Neurol Psychiatr 1998; 66: 233-40
15. 15. Rovner BW. Behavioral and psychiatric disability in Alzheimers disease. J Geriatr Psychiatry 1992; 25: 247-55
16. 16. Butler FR, Burgio LD, Engel BT. Neuroleptics and behavior: a comparative study. J Gerontol Nurs 1987; 13: 15-9
17. 17. Everitt DE, Fields DR, Soumerai SS, et al. Resident behavior and staff distress in the nursing home. J Am Geriatr Soc 1991; 39: 792-8
18. 18. Swearer JM, Drachman DA, ODonnell BF, et al. Troublesome and disruptive behaviors in dementia: relationships to diagnosis and disease severity. J Am Geriatr Soc 1988; 36: 784-90
19. 19. Merriam AE, Aronson MK, Gasten P, et al. The psychiatric symptoms of Alzheimers disease. J Am Geriatr Soc 1988; 36: 7-12
20. 20. Teri L, Borson S, Kiyak A, et al. Behavioral disturbance, cognitive dysfunction, and functional skill: prevalence and relationship in Alzheimers disease. J Am Geriatr Soc 1989; 37: 109-16
21. 21. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimers disease: IV. disorders of behaviour. Br J Psychiatry 1990; 157: 1063-9
22. 22. Devanand DP, Brockington CD, Moody BJ. Behavioral syndromes in Alzheimers disease. Int Psychogeriatrics 1992; 4: 161-84
23. 23. OLeary PA, Haley WE, Paul PB. Behavioral assessment in Alzheimers disease: use of a 24-hr log. Psychol Aging 1993; 8: 139-43
24. 24. Riter RN, Fries BE. Predictors of the placement of cognitively impaired residents on special care units. Gerontologist 1992; 32: 184-90
25. 25. Wagner AW, Teri L, Orr-Rainey N. Behavior problems of residents with dementia in special care units. Alzheimer Dis Assoc Disord 1995; 9: 121-7
26. 26. Devanand DP, Sackeim HA, Brown RP, et al. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimers disease. Arch Neurol 1989; 46: 854-7
27. 27. Yeager BF, Farnett LE, Ruzicka SA. Management of the behavioral manifestations of dementia. Arch Intern Med 1995; 155: 250-60
28. 28. Raskind MA. Management of late life depression and the non-cognitive behavioral disturbances of Alzheimers disease. Psychiatr Clin North Am 1993; 16: 815-27
29. 29. Cohen-Mansfield J. Agitated behaviors in the elderly, II: preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986; 34: 722-7
30. 30. Mintzer JE, Brawman-Mintzer O. Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. J Clin Psychiatry 1996; 57 Suppl. 7: 55-63
31. 31. German DG, Read S, Cummings JL. Cholinergic therapy of behavioural disturbances on Alzheimers disease. Neuropsych Neuropsychol Behav Neurol 1993; 6: 229-34
32. 32. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54: 465-73
33. 33. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30
34. 34. Katz IR, Rovner B. Psychiatric disorders in the nursing home: a selective review of studies related to clinical care. Int J Geriatr Psychiatry 1993; 8: 75-87
35. 35. McKhann G, Drachmann D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44
36. 36. Blacker D, Albert MS, Bassett S, et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimers disease. Arch Neurol 1994; 51: 1198-204
37. 37. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-60
38. 38. McKeith IG, Perry RH, Fairbairn AF, et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992; 22: 911-22
39. 39. McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity and interrater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994; 44: 872-7
40. 40. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines of the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996; 47: 1113-24
41. 41. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57: 416-8
42. 42. Miller BL, Ikonte C, Ponton M, et al. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. Neurology 1997; 48: 937-42
43. 43. Pasquier F, Petit H. Frontotemporal dementia: its rediscovery. Eur Neurol 1997; 38: 1-6
44. 44. McKeith IG, Fairbairn AF, Perry RH, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673-8
45. 45. McKeith IG, Ballard CG, Harrison RWS. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995; 346: 699
46. 46. Ballard CG, Grace J, McKeith IG, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimers disease. Lancet 1998; 351: 1032-3
47. 47. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimers disease. Neuroreport 1994; 5: 747-9
48. 48. Wilcock GK, Scott M. Tacrine for senile dementia of Alzheimers or Lewy body type [abstract]. Lancet 1994; 344: 544
49. 49. Stewart JT. Managing the care of patients with dementia: how to maximize level of functioning and minimize behavioral problems. Postgrad Med 1991; 90: 45-9
50. 50. Sunderland T. Treatment of the elderly suffering from psychosis and dementia. J Clin Psychiatry 1996; 57 Suppl. 9: 53-6
51. 51. Zayas EM, Grossberg GT. Treating the agitated Alzheimer patient. J Clin Psychiatry 1996; 57 Suppl. 7: 46-51
52. 52. Taft L, Delaney K, Seman D, et al. Creating a therapeutic milieu in dementia care. J Gerontol Nurs 1993; 19: 30-9
53. 53. Mintzer JE, Lewis L, Pennypacker L, et al. Behavioral intensive care unit (BICU): a new concept in management of acute agitated behavior in elderly demented patients. Gerontologist 1993; 33: 801-6
54. 54. Mace N, Rabins PV. The 36-hour day: a family guide to caring for persons with Alzheimers disease, related dementing illnesses and memory loss in later life. Baltimore (MD): Johns Hopkins University Press, 1991
55. 55. Rovner BW, Steele CD, Shmuely Y, et al. A randomized trial of dementia care in nursing homes. J Am Geriatr Soc 1996; 44: 7-13
56. 56. Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging. Arch Neurol 1974; 30: 113-21
57. 57. Perry EK, Tomlinson BE, Blessed G. Correlation of cholinergic abnormalities with senile plaques and mental test scores in dementia. BMJ 1978 11: 1457-9
58. 58. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990; 47: 209-14
59. 59. Palmer AM, Stratman GC, Procter AW, et al. Possible neurotransmitter basis of behavioral changes in Alzheimer disease. Ann Neurol 1988; 23: 6161-20
60. 60. Eichelman B. Neurochemical basis of aggressive behavior. Psychiatric Ann 1987; 17: 371-4
61. 61. Eichelman B. Toward a rational pharmacotherapy for aggressive and violent behavior. Hosp Community Psychiatry 1988; 39: 31-9
62. 62. Ellison DW, Deal MF, Mazurek MF, et al. A post-mortem study of amino acid neurotransmitters in Alzheimer disease. Ann Neurol 1986; 20: 616-21
63. 63. Hardy J, Cowburn R, Barton A, et al. A disorder of cortical GABAergic innervation in Alzheimer disease. Neurosci Lett 1987; 73: 192-6
64. 64. Murray MA, Peskind ER. Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Als Dis Assoc Disord 1994; 8 Suppl. 3: 54-60
65. 65. Elrod R, Peskind ER, DiGiacomo L, et al. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry 1997; 154: 25-30
66. 66. Sweet RA, Pollock BG, Mulsant BH, et al. Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report. Biol Psychiatry 1997; 42: 1016-23
67. 67. Herrmann N, Lanctot KL, Naranjo CA. Behavioural disorders in demented elderly patients: current issues in pharmacotherapy. CNS Drugs 1996; 6: 280-300
68. 68. Weiner ME, Koss E, Wild KV, et al. Measures of psychiatric symptoms in Alzheimer patients: a review. Alzheimer Dis Assoc Disord 1996; 10 (1): 20-30
69. 69. Reisberg B. Behavioral pathology in Alzheimers disease rating scale (BEHAVE-AD). J Clin Psychiatry 1987; 48 Suppl.: 9-15
70. 70. Allen RL, Walker Z, D'Ath PJ, et al. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 1995; 346: 185
71. 71. Brecher M, Clyde MS, the Risperidone Study Group. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Poster presented at the Eighth Congress of the International Psychogeriatric Association. Jerusalem, Israel, Aug 17-22, 1997
72. 72. De Deyn P, De Smedt G, the Risperidone Working Group. Risperidonc in the treatment of behavioral disturbances in dementia. Poster presented at the Eighth Congress of the International Psychogeriatric Association. Jerusalem, Israel, Aug 17-22, 1997
73. 73. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogerial 1992; 4: 187-95
74. 74. Honigfeld G, Klett J. The Nurses Observation Scale for Inpatient Evaluation (NOSIE). J Clin Psychol 1965; 21: 65-71
75. 75. Dingemans PM. The Brief Psychiatric Rating Scale (BPRS) and the Nurses Observation Scale for Inpatienl Evaluation (NOSIE) in the evaluation of positive and negative symptoms. J Clin Psychol 1990; 46: 168-74
76. 76. Hamot HB, Patin RJ, Singer MJ. Factor structure of the Sandoz Clinical Assessment Geriatric Scale (SCAG). Psychopharmacol Bull 1984; 1984; 20: 142-50
77. 77. Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment Geriatric Scale (SCAG). J Am Geriatr Soc 1974; 22: 107-13
78. 78. Cohen-Mansfield J, Werner P, Marx MS. An observational study of agitation in agitated nursing home residents. Int Psychogeriatr 1989; 1: 153-65
79. 79. Lavretsky H, Sulzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998; 6: 127-35
80. 80. Workman Jr RH, Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997; 9: 594-7
81. 81. Ferris SH, Mackell JA. Behavioral outcomes in clinical trials for Alzheimer disease. Alz Dis Assoc Disord 1997; 11 Suppl. 4: S10-15
82. 82. Yudofsky SC, Silver JM, Jackson W, et al. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986; 143: 35-9
83. 83. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS). Psychol Rep 1962; 10: 799-812
84. 84. National Institute of Mental Health (NIMH). CGI: clinical global impressions. In: Guy W, editor. EDCEU assessment in psychopharmacology. Rockville (MD): NIMH, 1970; 217-22
85. 85. Herrmann N, Rivard MF, Flynn M, et al. Risperidone for the treatment of behavioral disturbances in dementia: a case series. J Neuropsychiatry Clin Neurosci 1998; 10: 220-3
86. 86. Geizer M, Ancill RJ. Combination of risperidone and donepezil in Lewy body dementia. Can J Psychiatry 1998; 43: 421-2
87. 87. Gutzmann H, Kühl KP, Kanowski S, et al. Measuring the efficacy of pharmacological treatment of psychomotor restlessness in dementia: clinical evaluation of tiapride. Pharmacopsychiatry 1997; 30: 6-11
88. 88. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Psychol 1967; 6: 278-96
89. 89. Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 1992; 6: 55-64
90. 90. Burke WJ, Folks DG, Roccaforte WH, et al. Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dementia of the Alzheimer type. Am J Geriatr Psychiatry 1994; 2: 352-4
91. 91. Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58: 212-6
92. 92. Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimers disease and other dementia: a selective review. Int J Geriatr Psychiatry 1991; 6: 691-708
93. 93. Aisen PS, Johannessen DJ, Marin DB. Trazodone for behavioral disturbance in Alzheimers disease. Am J Geriatr Psychiatry 1993; 1(4): 349-50
94. 94. Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5: 60-9
95. 95. Levy MA, Burgio LD, Sweet R, et al. A trial of buspirone in the control of disruptive behaviors in community-dwelling patients with dementia. Int J Geriatr Psychiatry 1994; 9: 841-8
96. 96. Lawlor BA, Radcliffe J, Molchan SE, et al. A pilot placebo controlled study of trazodone and buspirone in Alzheimers disease. Int J Geriatr Psychiatry 1994; 9: 55-9
97. 97. Goad DL, Davis CM, Liem P, et al. The use of selegeline in Alzheimers patients with behaviour problems. J Clin Psychiatry 1991; 52: 342-5
98. 98. Burke W, Roccaforte WH, Wengel SP, et al. L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993; 41: 1219-25
99. 99. Greendyke RM, Kanter DR, Schuster DB, et al. Propanolol treatment of assaultive patients with organic brain disease. J Nerv Ment Dis 1986; 174: 290-4
100. 100. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double blind study. J Clin Psychiatry 1986; 47: 423-6
101. 101. Ratey JJ, Sorgi P, ODriscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind placebo-controlled study. J Clin Psychiatry 1992; 53: 41-6
102. 102. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimers outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51: 115-8
103. 103. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42: 1160-6
104. 104. Lemke MR. Effects of carbamazepine on agitation in Alzheimers inpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56: 354-7
105. 105. Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993; 6: 205-9
106. 106. Sandborn WD, Bendfeldt F, Hamdy R. Valproic acid for physically aggressive behaviour in geriatric patients. Am J Geriatr Psychiatry 1995; 3: 239-42
107. 107. Sival RC, Haffmans PMJ, Van Gent PP, et al. The effects of sodium valproate on disturbed behaviour in dementia. J Am Geriatr Soc 1994; 42: 906-7
108. 108. Porsteinsson AP, Tariot PN, Erb R, et al. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997; 5: 344-51
109. 109. Chesrow EJ, Kaplitz SE, Vetra H, et al. Blind study of oxazepam in the management of geriatric patients with behavioral problems. Clin Lab Med 1965; 72: 1001-5
110. 110. Sanders JF. Evaluation of oxazepam and placebo in emotionally disturbed aged patients. Geriatrics 1965; 20: 739-46
111. 111. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and risk of hip fracture. N Engl J Med 1987; 316: 363-9
112. 112. Calkin PA, Kunik ME, Orengo CA, et al. Tolerability of clonazepam in demented and non-demented geropsychiatric patients. Int J Geriatr Psychiatry 1997; 12: 745-9
113. 113. Kirven LE, Montero EF. Comparison of thioridazine and diazepam in the control of non-psychotic symptoms associated with senility. J Am Geriatr Soc 1973; 12: 546-51
114. 114. Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, non-psychotic patients with emotional and behavioral disorders. Clin Ther 1984; 6: 546-59
115. 115. Coccaro EF, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of non-cognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147: 1640-5
116. 116. Semla TP, Cohen D, Freels S, et al. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimers disease. Pharmacotherapy 1995; 15: 495-501
117. 117. Stoppe G, Sandholzer H, Staedt J, et al. Sleep disturbances in the demented elderly: treatment in ambulatory care. Sleep 1995; 18: 844-8
118. 118. Prien Y, Haber PA, Caffey EM. The use of psychoactive drugs in elderly patients with psychiatric disorders: survey conducted in twelve veterans administration hospitals. J Am Geriatr Soc 1975; 23: 104-12.
119. 119. Michel K, Kolakowska T. A survey of prescribing psychotropic drugs in two psychiatric hospitals. Br J Psychiatry 1981; 138: 217-21
120. 120. Gilleard CJ, Morgan K, Wade BE. Patterns of neuroleptic use among the institutionalized elderly. Acta Psychiatr Scand 1983; 68: 419-25
121. 121. Devanand DP, Sackeim HA, Mayeux R. Psychosis, behavioral disturbance, and the use of neuroleptics in dementia. Compr Psychiatry 1988; 29: 387-401
122. 122. Hesse KA, Driscoll A, Jacobson S. Neuroleptic prescriptions for acutely ill geriatric patients. Arch Intern Med 1993; 153: 2581-7
123. 123. Streim JE. OBRA regulations and psychiatric care in the nursing home. Psychiatric Ann 1995; 25: 413-8
124. 124. Risse SC, Cubberly L, Lampe TH, et al. Acute effects of neuroleptic withdrawal in elderly demented patients. J Geriatr Drug Ther 1989; 2: 65-77
125. 125. Semla TP, Palla K, Poddig B, et al. Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc 1994; 42: 648-52
126. 126. Thapa PB, Meador KG, Gideon P, et al. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc 1994; 42: 280-6
127. 127. Horwitz GJ, Tariot PN, Mead K, et al. Discontinuation of antipsychotics in nursing home patients with dementia. Am J Geriatr Psychiatry 1995; 3: 290-9
128. 128. Kumar V. Use of atypical antipsychotic agents in geriatric patients: a review. Int J Geriatr Psychopharmacol 1997; 1: 15-23
129. 129. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553-63
130. 130. Carlyle W, Ancill RJ, Sheldon L. Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. Int Clin Psychopharmacol 1993; 8: 103-8
131. 131. Finkel SI, Lyons JS, Anderson RL, et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995; 10: 129-36
132. 132. Helms PM. Efficacy of antipsychotics in the treatment of the behavioural complications of dementia: a review of the literature. J Am Geriatr Soc 1985; 33: 206-9
133. 133. Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139: 1170-4
134. 134. Petrie WM, Ban TA, Berney S, et al. Loxapine in psychogeriatrics: a placebo-and standard-controlled clinical investigation. J Clin Psychopharmcol 1982; 2: 122-6
135. 135. Maletta GJ. Pharmacologic treatment and management of the aggressive demented patient. Psychiatric Ann 1990; 20: 446-55
136. 136. Gershanik OS. Drug-induced parkinsonism in the aged: recognition and prevention. Drugs Aging 1994; 5: 127-32
137. 137. Avorn J, Monane M, Everitt DE, et al. Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch Intern Med 1994; 154: 1113-7
138. 138. Wong DF, Wagner HN, Dannals RE, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226: 1393-6
139. 139. Caligiuri MP, Lohr JB, Jeste DV. Instrumental evidence that age increases motor instability in neuroleptic-treated patients. J Gerontol 1991; 46: B197-200
140. 140. Nolan E, OMalley K. Prescribing for the elderly: part 1. sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142-9
141. 141. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402-6
142. 142. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987; 44: 418-26
143. 143. McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. BMJ 1997; 314: 266-70
144. 144. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996; 124: 2-34
145. 145. Lacru JP, Eastham JH, Jeste DV, et al. Newer antipsychotics and antidepressants for elderly people. Curr Opin Psychiatry 1996; 9: 290-3
146. 146. Robertsson B, Karlsson I, Eriksson L, et al. An atypical neuroleptic drug in the treatment of behavioural disturbances and psychotic symptoms in elderly people. Dementia 1996; 7: 142-6
147. 147. Bymaster FB, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14: 87-96
148. 148. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinsons disease. Mov Disord 1992; 7: 125-31
149. 149. Wagner ML, Defilippi JL, Menza MA, et al. Clozapine for the treatment of psychosis in Parkinsons disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996; 8: 276-80
150. 150. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinsons disease patients. Lancet 1994; 343: 1370-1
151. 151. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of six patients with Parkinsons disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556-9
152. 152. Jeanblanc W, Davis YB. Risperidone for treating dementia-associated agression [letter]. Am J Psychiatry 1995; 153: 8
153. 153. Marciniak BH, Guay DRP. Risperidone in the long-term care population. Consult Pharm 1995; 10: 1374-8
154. 154. Irizarry MC, Binetti T, Gomez-Isla T, et al. Treatment of behavioral disturbances in dementia with risperidone [abstract]. Neurology 1996; 46: 218
155. 155. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home resistents: a clinical experience. Int Psychogeriatr 1997; 9: 65-8
156. 156. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6
157. 157. Frankenburg FR, Kalunian D. Clozapine in the elderly. J Geriatr Psychiatry Neurol 1994; 7: 129-32
158. 158. Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995; 56: 180-5
159. 159. Chengappa KNR, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 1995; 8: 12-5
160. 160. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
161. 161. Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996; 57 Suppl. 3: 39-45
162. 162. Geroldi G, Frisoni B, Bianchetti A, et al. Drug treatment in Lewy body dementia. Dementia Geriatr Cogn Disord 1997; 8: 188-97
163. 163. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995; 3: 26-33
164. 164. Satterlee WG, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients [abstract]. Psychopharmacol Bull 1995; 31: 534
165. 165. Davis R, Markham A. Ziprasidone. CNS Drugs 1997; 8: 153-9